US Bioservices Announces Wins in Three Strategic Areas
US Bioservices, an independent pharmacy and a part of AmerisourceBergen, announced that 2017 was a record-breaking year for new business wins in three strategic areas-oncology, rare and orphan, and specialty infusion. US Bioservices received access to 28 new products in 2017, including 10 oncology products and three rare and orphan therapies.
US Bioservices’ portfolio offers:
- Specialty Infusion: US Bioservices has more than 25 years of experience providing specialty infusion therapies, including IV drugs, and self-administered infusion and injection medications, to patients nationwide. US Bioservices offers personalized clinical support, including self-infusion training, in-home infusion nursing services and 24/7 access to clinical support.
- Oncology: With more than 80 members, US Bioservices’ Oncology Patient Support Team provides clinical care that is specific to the patient’s needs, conditions, and therapies.
- Rare & Orphan: US Bioservices’ depth of experience supporting rare and orphan programs, combined with AmerisourceBergen’s Signature® commercialization solutions, provide a range of program and partnership options that can be tailored to maximize results.
Through comprehensive technology systems, US Bioservices’ manufacturer partners get a transparent view into the therapy experience.
US Bioservices leverages resources provided by AmerisourceBergen companies, including Lash Group for patient support services; ION Solutions and Oncology Support for their connections to community oncology providers, and ICS and ASD Healthcare for rare and orphan logistics and distribution.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
